Cullinan Oncology LLC
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $10.455
- Today's High:
- $10.84
- Open Price:
- $10.72
- 52W Low:
- $7.782
- 52W High:
- $15.89
- Prev. Close:
- $10.58
- Volume:
- 95638
Company Statistics
- Market Cap.:
- $458.55 million
- Book Value:
- 12.344
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $18.94 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -21.03%
- Return on Equity TTM:
- 14.13%
Company Profile
Cullinan Oncology LLC had its IPO on 2021-01-08 under the ticker symbol CGEM.
The company operates in the Healthcare sector and Biotechnology industry. Cullinan Oncology LLC has a staff strength of 62 employees.
Stock update
Shares of Cullinan Oncology LLC opened at $10.72 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $10.46 - $10.84, and closed at $10.53.
This is a -0.47% slip from the previous day's closing price.
A total volume of 95,638 shares were traded at the close of the day’s session.
In the last one week, shares of Cullinan Oncology LLC have slipped by -2.95%.
Cullinan Oncology LLC's Key Ratios
Cullinan Oncology LLC has a market cap of $458.55 million, indicating a price to book ratio of 0.9098 and a price to sales ratio of 26.8794.
In the last 12-months Cullinan Oncology LLC’s revenue was $0 with a gross profit of $18.94 million and an EBITDA of $-160084000. The EBITDA ratio measures Cullinan Oncology LLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cullinan Oncology LLC’s operating margin was 0% while its return on assets stood at -21.03% with a return of equity of 14.13%.
In Q1, Cullinan Oncology LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cullinan Oncology LLC’s PE and PEG Ratio
- Forward PE
- 6.3012
- Trailing PE
- 9.1016
- PEG
Its diluted EPS in the last 12-months stands at $1.28 per share while it has a forward price to earnings multiple of 6.3012 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cullinan Oncology LLC’s profitability.
Cullinan Oncology LLC stock is trading at a EV to sales ratio of 11.5457 and a EV to EBITDA ratio of 0.284. Its price to sales ratio in the trailing 12-months stood at 26.8794.
Cullinan Oncology LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $514.99 million
- Total Liabilities
- $26.17 million
- Operating Cash Flow
- $15.18 million
- Capital Expenditure
- $159000
- Dividend Payout Ratio
- 0%
Cullinan Oncology LLC ended 2024 with $514.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $514.99 million while shareholder equity stood at $485.65 million.
Cullinan Oncology LLC ended 2024 with $0 in deferred long-term liabilities, $26.17 million in other current liabilities, 4000.00 in common stock, $-105657000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $122.13 million and cash and short-term investments were $390.70 million. The company’s total short-term debt was $3,403,000 while long-term debt stood at $0.
Cullinan Oncology LLC’s total current assets stands at $399.03 million while long-term investments were $110.44 million and short-term investments were $268.57 million. Its net receivables were $0 compared to accounts payable of $2.03 million and inventory worth $0.
In 2024, Cullinan Oncology LLC's operating cash flow was $15.18 million while its capital expenditure stood at $159000.
Comparatively, Cullinan Oncology LLC paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $10.53
- 52-Week High
- $15.89
- 52-Week Low
- $7.782
- Analyst Target Price
- $28.5
Cullinan Oncology LLC stock is currently trading at $10.53 per share. It touched a 52-week high of $15.89 and a 52-week low of $15.89. Analysts tracking the stock have a 12-month average target price of $28.5.
Its 50-day moving average was $10.58 and 200-day moving average was $10.85 The short ratio stood at 13.48 indicating a short percent outstanding of 0%.
Around 1186.8% of the company’s stock are held by insiders while 8193.3% are held by institutions.
Frequently Asked Questions About Cullinan Oncology LLC
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company’s lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company’s preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.